Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Thursday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX stock opened at $0.33 on Thursday. The company has a fifty day moving average price of $0.51 and a two-hundred day moving average price of $1.17. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The stock has a market cap of $19.40 million, a P/E ratio of -0.15 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.